MILESTONE, ROYALTY AND SUBLICENSING FEE DEEDMilestone, Royalty and Sublicensing Fee Deed • September 15th, 2015 • Transition Therapeutics Inc. • Medicinal chemicals & botanical products • New York
Contract Type FiledSeptember 15th, 2015 Company Industry JurisdictionThis MILESTONE, ROYALTY AND SUBLICENSING FEE deed (this “Deed”) is made and entered into as of February 27, 2014, by and between Elan Pharma International Limited, a private limited company incorporated in Ireland (“EPIL”), and Elan Science Ten Limited, a private limited company incorporated in Ireland (the “Company”). EPIL and the Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties”. Capitalized terms used in this Deed have the meanings ascribed to them in ARTICLE IV.